"Three batches have been produced—not meant for human injection, but to test how the equipment works and to establish the necessary quality controls, confirming that the vaccine meets all verified parameters. This has been done. The vaccine that will be given to people will be produced in the new year," Gintsburg stated.
Earlier, Russia’s Ministry of Health granted approval for the clinical use of the mRNA vaccine Neooncovac for melanoma therapy, developed by the same center.